Dr.Finance (WAR:DRF) Research & Development: zł0.00 Mil (TTM As of Dec. 2025)


WAR:DRF Dr.Finance SA WAR:DRF
36 GF Score
Price zł1.17
GF Value zł0.50
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Dr.Finance Research & Development?

Dr.Finance WAR:DRF +1.30% 36 Research & Development is zł0.00 Mil as of Dec. 2025. GuruFocus rates WAR:DRF with a GF Score™ of 36/100 and a GF Value™ of zł0.50 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Dr.Finance's Research & Development for the three months ended in Dec. 2025 was zł0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was zł0.00 Mil.

Dr.Finance  (WAR:DRF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Dr.Finance Research & Development Related Terms

Dr.Finance Research & Development Historical Data

* Premium members only.

The historical data trend for Dr.Finance's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr.Finance Research & Development Chart

Dr.Finance Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Dr.Finance Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WAR:DRF
36GF Score
Dr.Finance SA WAR:DRF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dr.Finance Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of zł0.00 Mil mean?
Dr.Finance (WAR:DRF) has a Research & Development of zł0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Dr.Finance and its competitors.
Is Dr.Finance's Research & Development too high?
Dr.Finance's current Research & Development is zł0.00 Mil. Overall, Dr.Finance has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr.Finance's Research & Development compare to V and MA?
Dr.Finance's Research & Development of zł0.00 Mil can be compared against companies in the Credit Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Credit Services company?
A good Research & Development depends on the Credit Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Dr.Finance and its competitors. Dr.Finance's current Research & Development is zł0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr.Finance stock overvalued right now?
Based on GuruFocus' analysis, Dr.Finance (WAR:DRF) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.50, compared to a current price of zł1.17 — trading 133% above its estimated fair value. The current Research & Development is zł0.00 Mil. Dr.Finance's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Dr.Finance (WAR:DRF), the current Research & Development is zł0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dr.Finance (WAR:DRF) Overvalued in 2026?

Based on GuruFocus' analysis, Dr.Finance stock appears to be overvalued. The current stock price of zł1.17 is trading 133% above its estimated GF Value™ of zł0.50. GuruFocus considers Dr.Finance to be Significantly Overvalued.

Key valuation signals for WAR:DRF:

  • Research & Development: zł0.00 Mil
  • GF Value™: zł0.50 vs. price of zł1.17 (133% above fair value)
  • GF Score™: 36/100 with 3 warning signs

No single metric tells the full story. See the WAR:DRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dr.Finance Business Description

Address ul. Braniborska 65/12, Wroclaw, POL, 53-680
Dr.Finance SA is a financial intermediary in the sale of loans and other financial products. It operates in the business of Working capital loans, Investment loans, Leasing, and Factoring.
36GF Score

Get the complete analysis for WAR:DRF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł1.17
Price
zł0.50
GF Value